Selective estrogen receptor modulators in chronic renal failure

Página do item simplificado
dc.contributor.authorWeisinger, Jose R
dc.contributor.authorHeilberg, Ita Pfeferman [UNIFESP]
dc.contributor.authorHernandez, Eddy
dc.contributor.authorCarlini, Raul
dc.contributor.authorBellorin-Font, Ezequiel
dc.contributor.institutionUniv Munich
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionSan Carlo Borromeo Hosp
dc.date.accessioned2018-06-18T10:54:38Z
dc.date.available2018-06-18T10:54:38Z
dc.date.issued2003-06-01
dc.description.abstractBackground. In addition to renal osteodystrophy, postmenopausal women on dialysis could be at risk of osteoporosis. Hormone replacement therapy (HRT) could have beneficial effects as well as potentially serious risks, especially in uremic women, due to the pharmacokinetics of estradiol in renal failure. Therapeutic alternatives, such as the selective estrogen receptor modulators (SERMs), have shown the benefits of estrogen on bone and serum lipid levels, without its adverse effects on the breast and endometrium, in nonuremic women.Methods. Recent data on the effect of the SERM raloxifene in bone and lipid metabolism in osteoporotic postmenopausal women on dialysis is reviewed. Since the estrogen receptor (ER) gene has been suggested as a candidate marker for osteoporosis, we investigated whether ER polymorphism could have predicted the BMD response to raloxifene.Results. Hemodialyzed women on raloxifene demonstrated increased trabecular bone mineral density (BMD) and decreased bone resorption markers. Similarly, LDL-cholesterol values dropped significantly. ER gene polymorphism analysis of baseline BMD parameters did not differ between PP/xx or Pp/Xx groups. Nevertheless, patients on raloxifene with PP/xx genotypes, but not those with Pp/Xx, showed a higher trabecular BMD after one year on treatment, suggesting that homozygous women for P or x alleles of the ER have a better BMD response to raloxifene.Conclusion. Raloxifene and, most likely, other SERMs, could represent a good alternative to HRT in postmenopausal uremic women.en
dc.description.affiliationCent Univ Venezuela, Hosp Univ Caracas, Div Nephrol, Caracas 1040, Venezuela
dc.description.affiliationUniv Fed Sao Paulo, Div Nephrol, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Div Nephrol, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent514-523
dc.identifierhttp://dx.doi.org/10.1046/j.1523-1755.63.s85.15.x
dc.identifier.citationKidney International. New York: Nature Publishing Group, v. 63, p. S62-S65, 2003.
dc.identifier.doi10.1046/j.1523-1755.63.s85.15.x
dc.identifier.issn0085-2538
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/44808
dc.identifier.wosWOS:000182994200015
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.ispartofKidney International
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectosteoporosisen
dc.subjectbone mineral densityen
dc.subjecthemodialysisen
dc.subjectmenopauseen
dc.subjecthormone replacement therapyen
dc.subjectselective estrogen receptor modulatoren
dc.subjectraloxifeneen
dc.titleSelective estrogen receptor modulators in chronic renal failureen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos